Table 4 Association between psychosis sub-syndromes with AD biomarkers and CSVD markers in whole sample

Age

0.013 (-0.014, 0.041)

0.338

-

-

-

-

Sex

-0.061 (-0.490, 0.369)

0.782

-

-

-

-

Education

-0.035 (-0.115, 0.046)

0.400

-

-

-

-

APOE ε4 carrier status

-0.006 (-0.434, 0.422)

0.977

-

-

-

-

Clinical diagnosis

0.030 (-0.439, 0.499)

0.900

-

-

-

-

Aβ₄₂ (pg/ml)

-0.001 (-0.005, 0.003)

0.676

-0.001 (-0.006, 0.44)

0.763

-

-

p-tau₁₈₁ (pg/ml)

-0.002 (-0.009, 0.006)

0.670

-0.002 (-0.010, 0.006)

0.629

-

-

t-tau (pg/ml)

0.001 (-0.004, 0.004)

0.979

0.000 (-0.005, 0.004)

0.825

-

-

p-tau₁₈₁/Aβ₄₂

-0.141 (-0.998, 0.715)

0.746

-0.200 (-1.158, 0.759)

0.683

-

-

t-tau/Aβ₄₂

-0.012 (-0.416, 0.391)

0.952

-0.061 (-0.525, 0.403)

0.795

-

-

PVL-WMH score

0.092 (-0.163, 0.347)

0.479

-0.190 (-0.475, 0.096)

0.192

-

-

DWM-WMH score

0.113 (-0.134, 0.360)

0.369

0.025 (-0.275, 0.325)

0.872

-

-

BG-PVS score

0.059 (-0.409, 0.527)

0.804

0.020 (-0.455, 0.495)

0.935

-

-

CSO-PVS score

-0.155 (-0.433, 0.124)

0.275

-0.190 (-0.474, 0.096)

0.192

-

-

Microbleeds

0.529 (-0.028, 1.087)

0.063

0.440 (-0.102, 0.982)

0.112

-

-

Lacune

0.308 (-0.233, 0.848)

0.264

0.253 (-0.309, 0.816)

0.377

-

-